Sanofi Administrative Office
Gdansk, Poland
NCT Number: NCT03514732
Primary Objective:
To estimate the range of improvement of NOVANUIT® triple action on sleep quality global score.
Secondary Objectives:
* To estimate the range of improvement of NOVANUIT® triple action on following parameters: time for getting asleep, sleep time, number of nocturnal awakening, number of nightmares, sleep quality (score from 0 to 10), and mean tiredness during the day (score from 0 to 10). * To estimate persistency of NOVANUIT® triple action effects after end of study product consumption. * To assess dependency to NOVANUIT® triple action after study product cessation. * To assess tolerance of NOVANUIT® triple action during the study.
Looking for future studies?
Notify Me20 year–75 year
All sexes
Interventional
Phase 1
Gdansk, Poland
Study participation duration for each participant will be 4 weeks including a 2-week treatment period.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Pharmaceutical form:Capsule Route of administration: Oral
Time frame: From baseline to Day 21
Difference in the average score of sleep quality
Time frame: From baseline to Day 28
Difference in the average score of sleep quality
Time frame: From baseline to Day 28
Difference in the average score of time for getting asleep
Time frame: From baseline to Day 28
Difference in the average score of sleep time
Time frame: From baseline to Day 28
Difference in the average score of number of nocturnal awakening
Time frame: From baseline to Day 28
Difference in the average score of number of nightmares
Time frame: From baseline to Day 28
Difference in the average score of awakening quality
Time frame: From baseline to Day 28
Difference in the average score of mean tiredness
Time frame: From baseline to Day 28
Number of participants with AEs
Time frame: At Day 28
Assessment of product's effects dependency at Day 28
Sanofi
Industry
An Open Label, Single Arm, Exploratory Study to Estimate the Range of Improvement of the Quality of Sleep With NOVANUIT® Triple Action in Subjects With Mild to Moderate Sleep Disorders
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07638605
Behavior, Mental Disorders
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07708623
Mental Disorders, Nervous System Diseases
Moscow, Russia
View Trial DetailsNCT02181569
Alcohol-Related Disorders, Alcoholism
Bethesda, Maryland, United States
View Trial DetailsNCT07695103
Mental Disorders, Nervous System Diseases
Guangzhou, Guangdon, China
View Trial Details